Cosmos Health Continues UK Retail Expansion for C-Scrub; Now Available at Superdrug, the UK’s Second-Largest Beauty and Health Retailer
Rhea-AI Summary
Cosmos Health (NASDAQ:COSM) announced that its antimicrobial cleanser C-Scrub Wash Chlorhexidine 4% is now available through Superdrug in the UK as of Feb 18, 2026. Superdrug operates more than 830 stores and a strong online platform, including over 200 in-store pharmacies.
This listing expands C-Scrub’s retail and pharmacy reach in the UK and Ireland, increasing brand exposure across broad-based and health-focused consumer channels and supporting regional product development plans.
Positive
- Listing at Superdrug's network of >830 stores and online platform
- Availability in Superdrug's >200 in-store pharmacies enhances pharmacy reach
- Expanded UK and Ireland retail footprint increases product exposure regionally
Negative
- None.
News Market Reaction – COSM
In the Feb 18 session, COSM gained 9.53%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.3% during that session. Argus tracked a trough of -5.9% from its starting point during tracking. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Crypto Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 17 | Brand portfolio showcase | Positive | -4.8% | Presented expanding nutraceutical and wellness brands at World Health Expo Dubai. |
| Feb 11 | Crypto asset purchase | Positive | -2.2% | Expanded digital assets program with additional Bitcoin investment and broader crypto strategy. |
| Jan 20 | Operational growth update | Positive | -5.6% | Reported customer growth, better unit economics and robotics expansion supporting extra revenue. |
| Jan 14 | Analyst coverage | Positive | -4.7% | Zacks Small-Cap Research initiated coverage with valuation and revenue growth projections. |
| Jan 05 | Manufacturing agreement | Positive | +3.0% | Signed PathMuscle manufacturing deal with minimum and expected multi‑year unit volumes. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent crypto-tagged and operational headlines have generally been positive, yet COSM often traded lower in the following session, indicating frequent divergence between news tone and price reaction.
Over the past months, Cosmos Health issued multiple crypto-tagged updates, including portfolio showcasing at World Health Expo Dubai, expansion of its digital assets program, operational growth at Cosmofarm, Zacks-initiated research coverage with detailed revenue projections, and a manufacturing agreement for PathMuscle with multi‑year volume expectations. Most of these updates were strategically positive, yet four of the five saw negative next‑day moves, highlighting a pattern where constructive news did not consistently translate into supportive price action.
Key Terms
antimicrobial medical
chlorhexidine medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHICAGO, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced continued expansion of its United Kingdom (UK) retail footprint as its antimicrobial skin cleanser, C-Scrub Wash Chlorhexidine
Established over 60 years ago, Superdrug is widely recognized for its leadership in health, wellness, and personal care categories and operates more than 830 stores across the UK and the Republic of Ireland, including over 200 in-store pharmacies and a growing number of health clinics, complemented by a strong online e-commerce platform.
C-Scrub Listed on Superdrug.com
C-Scrub is a powerful antiseptic wash offering reliable skin disinfectant properties. It is designed to reduce bacteria and help prevent infection, supporting effective skin hygiene. Expanding into Superdrug’s extensive retail and pharmacy network represents a strategic enhancement of Cosmos Health’s UK market positioning and further increases C-Scrub’s exposure within a focused consumer healthcare environment.
Greg Siokas, CEO of Cosmos Health, stated: “Our entry into Superdrug further reinforces the growing retail momentum for C-Scrub in the UK. Establishing presence across online, broad-based, and health-focused retail platforms significantly strengthens our market positioning. This continued expansion increases brand reach and supports the long-term development of our broader product portfolio across the region.”
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of any new information, future events, or otherwise.
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/28921cdd-6f72-4904-aac4-f42521cc53b9
